Clinical Trials Logo

Pulmonary Arterial Hypertension clinical trials

View clinical trials related to Pulmonary Arterial Hypertension.

Filter by:

NCT ID: NCT06122922 Withdrawn - Clinical trials for Pulmonary Artery Hypertension

Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)

Start date: March 15, 2024
Phase: Phase 2
Study type: Interventional

The objective of this project is to determine how pulmonary vascular remodeling in Pulmonary Arterial Hypertension (PAH) at cellular and pathological level is associated with gas exchange physiology changes and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.

NCT ID: NCT06104228 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

Xenon PAH Bio
Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additional assessments, such as labs, echocardiography, and six-minute walk distance (6MWD).

NCT ID: NCT06092424 Active, not recruiting - Clinical trials for Pulmonary Arterial Hypertension

High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA)

Start date: September 23, 2023
Phase: N/A
Study type: Interventional

To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live >2500m on pulmonary artery pressure (PAP) and other hemodynamics.

NCT ID: NCT06084559 Active, not recruiting - Clinical trials for Chronic Thromboembolic Pulmonary Hypertension

HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)

Start date: July 5, 2023
Phase: N/A
Study type: Interventional

To study the effect of SOT in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live >2500m on pulmonary artery pressure (PAP) and other hemodynamics by echocardiography and in relation to blood gases at 2840m with and without SOT.

NCT ID: NCT06072937 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

IntelliStent for Pulmonary Flow Adjustment in Congenital Heart Disease and Dilated Cardiomyopathy

HEARTFUL-CHD
Start date: June 4, 2024
Phase: N/A
Study type: Interventional

IntelliStent is intended to achieve reduction of pulmonary hypertension, improvements in symptoms and quality of life in pediatric, adolescent and adult patients with congenital heart disease associated pulmonary arterial hypertension or left ventricular dilated cardiomyopathy.

NCT ID: NCT06072417 Active, not recruiting - Clinical trials for Chronic Thromboembolic Pulmonary Hypertension

HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)

Start date: September 22, 2023
Phase: N/A
Study type: Interventional

To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live >2500m on sleep disordered breathing

NCT ID: NCT06053580 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

Repurposing Valsartan May Protect Against Pulmonary Hypertension

REVAMP-PH
Start date: February 28, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.

NCT ID: NCT06035861 Not yet recruiting - Clinical trials for Pulmonary Artery Hypertension

Endothelial Cell Activation and Total Pulmonary Resistance in PAH

Start date: November 1, 2024
Phase: N/A
Study type: Interventional

To determine whether changes in endothelial cell dysfunction are associated with changes in total pulmonary resistance in patients with pulmonary arterial hypertension

NCT ID: NCT06009185 Completed - Clinical trials for Pulmonary Arterial Hypertension

Safety and Efficacy of BIA 5-1058 in PAH

Start date: June 26, 2019
Phase: Phase 2
Study type: Interventional

This study aims to assess the safety and tolerability of the individual highest tolerated zamicastat doses, achieved in the study BIA-51058-201, during long-term treatment in Pulmonary Arterial Hypertension (PAH) disease.

NCT ID: NCT06003244 Active, not recruiting - Clinical trials for Chronic Thromboembolic Pulmonary Hypertension

High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)

Start date: September 23, 2023
Phase: N/A
Study type: Interventional

The investigators aim to study the effect of SOT in participants with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live >2500m on 6-minute walk distance (6MWD) assessed at 2840m.